Alexion buys Wilson Therapeutics
Alexion Pharmaceuticals Inc. offered SEK232 ($27.84) per share to acquire Wilson Therapeutics AB, a Swedish biotech developing its sole candidate for the rare genetic condition Wilson disease. The deal is valued at SEK6.56bn (equity value SEK7.1bn on a fully diluted basis), and the share price represents a 62% premium to Wilson’s ten-day pre-announcement market average.
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.